OncologyConsults




Head & Neck CME
CME Activities

Appropriate Use of Immune Therapy to Treat Head and Neck Cancer CME Credits: 0.5
While the introduction of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit.
Faculty: David S. Ettinger, MD Expires: 9/7/2018